Cargando…

NXPH4 Used as a New Prognostic and Immunotherapeutic Marker for Muscle-Invasive Bladder Cancer

BACKGROUND: One of the most common malignant tumors of the urinary system is muscle-invasive bladder cancer (MIBC). With the increased use of immunotherapy, its importance in the field of cancer is becoming abundantly evident. This study classifies MIBC according to GSVA score from the perspective o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gui, Zhiming, Ying, Xiaoling, Liu, Chunxiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553512/ https://www.ncbi.nlm.nih.gov/pubmed/36245981 http://dx.doi.org/10.1155/2022/4271409

Ejemplares similares

NXPH4 Promotes Gemcitabine Resistance in Bladder Cancer by Enhancing Reactive Oxygen Species and Glycolysis Activation through Modulating NDUFA4L2
por: Wang, Decai, et al.
Publicado: (2022)

Increased Expression of NXPH4 Correlates with Immune Cell Infiltration and Unfavorable Prognosis in Hepatocellular Carcinoma
por: Tang, Qin, et al.
Publicado: (2022)

Serum Proteins, HMMR, NXPH4, PITX1 and THBS4; A Panel of Biomarkers for Early Diagnosis of Hepatocellular Carcinoma
por: Eun, Jung Woo, et al.
Publicado: (2022)

Immunotherapeutic strategies for bladder cancer
por: Chevalier, Mathieu F, et al.
Publicado: (2014)

An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle‐invasive bladder cancer (MIBC)
por: Jiang, Wen, et al.
Publicado: (2020)

Triple‐marker immunohistochemical assessment of muscle‐invasive bladder cancer: Is there prognostic significance?
por: Labban, Muhieddine, et al.
Publicado: (2021)

Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer
por: Chen, Jiang, et al.
Publicado: (2022)

Plasma Triglyceride Levels May Be Modulated by Gene Expression of IQCJ, NXPH1, PHF17 and MYB in Humans
por: Vallée Marcotte, Bastien, et al.
Publicado: (2017)

Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies
por: Viveiros, Nicole, et al.
Publicado: (2022)

Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen
por: Chae, Han Kyu, et al.
Publicado: (2022)

FAM70B as a Novel Prognostic Marker for Cancer Progression and Cancer-Specific Death in Muscle-Invasive Bladder Cancer
por: Kang, Ho-Won, et al.
Publicado: (2012)

Prognostic value of prostate volume in non-muscle invasive bladder cancer
por: Ham, Won Sik, et al.
Publicado: (2021)

Exploration of Prognostic Biomarkers of Muscle-Invasive Bladder Cancer (MIBC) by Bioinformatics
por: Xu, Xianglai, et al.
Publicado: (2021)

Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
por: Katayama, Satoshi, et al.
Publicado: (2022)

The prognostic impact of tumor necrosis in non-muscle invasive bladder cancer
por: Culpan, Meftun, et al.
Publicado: (2022)

Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer
por: Ying, Yidie, et al.
Publicado: (2023)

Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer
por: Chen, Xuanzhao, et al.
Publicado: (2023)

Prognostic and Immunotherapeutic Roles of KRAS in Pan-Cancer
por: Yang, Kaixin, et al.
Publicado: (2022)

mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer
por: Ha, Yun-Sok, et al.
Publicado: (2010)

Involvement of haptoglobin phenotypes and genotypes in non-muscle invasive bladder cancer: A possible prognostic marker for risk stratification
por: Aghaalikhani, Nazi, et al.
Publicado: (2020)

Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer
por: Azuma, Takeshi, et al.
Publicado: (2020)

Integrative Transcriptome Profiling Reveals SKA3 as a Novel Prognostic Marker in Non-Muscle Invasive Bladder Cancer
por: You, Chaelin, et al.
Publicado: (2021)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Pancancer Analysis of the Prognostic and Immunotherapeutic Value of Progestin and AdipoQ Receptor 4
por: Yang, Ziyue, et al.
Publicado: (2022)

Selected protein expression in a new prognostic model for patients with non-muscle-invasive bladder cancer
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2020)

N6-methyladenosine-related non-coding RNAs are potential prognostic and immunotherapeutic responsiveness biomarkers for bladder cancer
por: Lu, Miaolong, et al.
Publicado: (2021)

Inflammatory Markers and Thromboembolic Risk in Patients with Non-Muscle-Invasive Bladder Cancer
por: Balan, Daniel, et al.
Publicado: (2021)

The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer
por: Zhang, Jingqi, et al.
Publicado: (2020)

Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer
por: Quhal, Fahad, et al.
Publicado: (2021)

Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer
por: AZhaTi, BaiHeTiYa, et al.
Publicado: (2022)

Comment on “The prognostic impact of tumor necrosis in non-muscle invasive bladder cancer”
por: Wang, Dexin, et al.
Publicado: (2023)

TEAD4 as a Prognostic Marker Promotes Cell Migration and Invasion of Urinary Bladder Cancer via EMT
por: Huang, Zhengnan, et al.
Publicado: (2021)

Preoperative Systemic Inflammatory Markers as a Significant Prognostic Factor After TURBT in Patients with Non-Muscle-Invasive Bladder Cancer
por: Ding, Li, et al.
Publicado: (2023)

Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non‐muscle‐invasive bladder cancer
por: Ye, Kun, et al.
Publicado: (2022)

Diagnostic and Prognostic Markers in Bladder Cancer
por: Ku, Ja Hyeon, et al.
Publicado: (2016)

PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer
por: Pignot, Géraldine, et al.
Publicado: (2019)

Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer
por: Zhang, Liang-Hao, et al.
Publicado: (2021)

Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer
por: Zhu, Huier, et al.
Publicado: (2019)

Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
por: El-Taji, Omar M. S., et al.
Publicado: (2016)

Non-invasive biomarkers for monitoring the immunotherapeutic response to cancer
por: Nisar, Sabah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_80qenl5qcul8m9l3ogfpk82tj8